Literature DB >> 12516682

Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.

Mahmut Tobu1, Omer Iqbal, Debra A Hoppensteadt, Christopher Shultz, Walter Jeske, Jawed Fareed.   

Abstract

Synthetic direct inhibitors of factor Xa are capable of prolonging the global anticoagulant assay times in a concentration-dependent fashion. The relative degree of thrombin generation inhibition at an equivalent prolongation is not similar to the results observed with heparins and oral anticoagulant drugs. In addition, the direct factor Xa inhibitors prolong the Russell's viper venom test (RWT) and Heptest clotting times. Ecarin clotting time (ECT) and thrombin time (TT) remain unaffected. The kinetics of factor Xa inhibition are markedly different than those observed with pentasaccharide and heparins. Therefore, the methods developed for heparins and pentasaccharides may not be applicable for the monitoring of factor Xa inhibitors. To test the feasibility of using the prothrombin time (PT), International Normalized Ratio (INR), activated partial thromboplastin time (aPTT), Heptest, thrombin time, RVVT, ECT, and a modified anti-Xa amidolytic assay, to monitor a synthetic factor Xa inhibitor, normal human pool plasma samples were spiked with a synthetic factor Xa inhibitor in the concentration range of 0 to 1 microg/mL and 0 to 25 microg/mL. Different laboratory tests were performed and INR and other ratios were calculated. The anticoagulant effects on whole blood were measured using the activated clotting time (ACT). Further studies on the effect of factor Xa inhibitor on platelet aggregation; factor II, VII, and X functional levels; and fibrinopeptide A (FPA) generation were carried out at equivalent INR levels in comparison to oral anticoagulant and antithrombin agents. FPA generation at equivalent anticoagulant level in comparison to heparin (twice the baseline) was also carried out. Factor Xa inhibitor produced a concentration-dependent prolongation of the ACT. ACT was doubled at a concentration of 4 to 5 microg/mL. There was a marked difference in the prolongation of the PT by a synthetic factor Xa inhibitor dependent on the ISI of the PT reagent used. When the results were calculated to determine INR, marked variations were noted between the recombinant thromboplastin and rabbit brain thromboplastin. The rabbit brain thromboplastin reagent gave markedly high INR values. Similar results were observed when different aPTT reagents were studied. In the anti-Xa assay, modification of the incubation time was employed to extend the proper sensitivity range. These studies warrant further investigation to understand the mechanism of action of factor Xa inhibitors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12516682     DOI: 10.1177/107602960200800404

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  3 in total

1.  Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.

Authors:  Kan He; Joseph M Luettgen; Donglu Zhang; Bing He; James E Grace; Baomin Xin; Donald J P Pinto; Pancras C Wong; Robert M Knabb; Patrick Y S Lam; Ruth R Wexler; Scott J Grossman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-04-02       Impact factor: 2.441

2.  Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

Authors:  Wolfgang Mueck; Bengt I Eriksson; Kenneth A Bauer; Lars Borris; Ola E Dahl; William D Fisher; Michael Gent; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Peter Kälebo; Louis M Kwong; Frank Misselwitz; Alexander G G Turpie
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of GCC-4401C, a Novel Direct Factor Xa Inhibitor, in Healthy Volunteers.

Authors:  H Y Choi; S Choi; Y H Kim; H S Lim
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-08-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.